A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.

Chunmei Bai, Jin Li, Heshui Wu et al.|Journal of Clinical Oncology|2024

Cited by 16